arrow
R

Riccardo Dolcetti

The University of Queensland
H指数:60
被引数:1.4万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

The neoantigen and associated tumour microenvironment in long-term survivors with oesophageal adenocarcinoma

食管腺癌长期生存者中的新抗原及其相关肿瘤微环境

2026-11-100
OAAI
H3K27M Mutation Modulates the Antigenic Landscape in Diffuse Midline Glioma

中线弥漫性胶质瘤中H3K27M突变调控抗原景观

Cancers
IF4.4
2026-09-290
OA
Probe-Based Confocal Laser Endomicroscopy During Immune Checkpoint Inhibitor Therapy: A Translational Framework Linking Intestinal Barrier Function, Microbiota, and Clinical Outcomes

基于探针的共聚焦激光内窥镜在免疫检查点抑制剂治疗期间的应用:连接肠道屏障功能、微生物组和临床结局的转化研究框架

2026-09-210
OA
Identification of immunodominant ERV peptides critical for anti-metastatic immunity in a model of TNBC

鉴定在TNBC模型中对于抗转移免疫至关重要的免疫优势ERV肽段

2026-09-200
OAAI
Control of poorly immunogenic tumors with systemic STING agonist-loaded liposomes targeting cross-presenting dendritic cells

通过靶向交叉呈递树突状细胞的全身性STING激动剂负载脂质体控制低免疫原性肿瘤

2026-08-200
OAAI
Brain-Resident MAIT Cells Infiltrate GL261 Tumors, and Activated MAIT Cell Signatures Are Associated With Improved Outcomes in Glioma

脑内定居的MAIT细胞浸润GL261肿瘤,且活化的MAIT细胞特征与胶质瘤的改善预后相关

2026-03-011
PRE
Antibody dependent cellular cytotoxicity-inducing anti-EGFR antibodies as effective therapeutic option for cutaneous melanoma resistant to BRAF inhibitors
2024-03-060
OAAI
The oesophageal adenocarcinoma tumour immune microenvironment dictates outcomes with different modalities of neoadjuvant therapy - results from the AGITG DOCTOR trial and the cancer evolution biobank

食管腺癌肿瘤免疫微环境决定了不同新辅助治疗方式的结果-来自AGITG DOCTOR试验和癌症进化生物库的结果

2023-10-126
OAAI